
The fiery secret to a longer life might be hiding in your spice rack
Spicy foods can help with weight control, plus reduce the risk of cancer and heart disease, studies have shown — and consuming more spices may also contribute to a longer lifespan.
Bryan Quoc Le, Ph.D., a food scientist with Mendocino Food Consulting, spoke to Fox News Digital about the benefits of spice and how to incorporate more heat into your diet.
The California-based expert cited studies that uncovered the ability of capsaicin — found in chili peppers — to alter mice's microbiomes by boosting beneficial bacteria while diminishing harmful bacteria.
"This, in turn, results in a greater release of an amino acid called tryptophan, which these beneficial bacteria produce," he said.
"Tryptophan is an important precursor to neurotransmitters, such as serotonin, which [are] involved in mood, sleep and digestion."
Capsaicin, the compound that causes heat in peppers, can also provide "serious benefits" when consumed at a low daily dose of 0.01%, the food scientist said.
"A good quality hot sauce should add both flavor and heat and blend well with the flavors of the dish."
"That's just enough heat to taste, but not so much to overwhelm your stomach," Le noted.
What dishes taste best with spice? Le suggested meat-forward savory dishes, including stews, chilis, roast chicken and tacos.
"A good quality hot sauce should add both flavor and heat and blend well with the flavors of the dish," he advised.
For those who are completely unaccustomed to spice, Le suggested pickled pepperoncinis as an easy introduction to hotter foods.
"They're mild, a bit acidic and pack bold flavor without leaving you with a heavy residue of spice that you need to rinse out with milk," Le said.
"From there, you can venture into poblano, serrano or jalapeño peppers. These are great seared to tone down the heat, but still lend delicious flavor to a dish."
The peppers that pack a serious punch include scotch bonnets, habaneros, ghost peppers and Carolina reapers, which are "not for the faint of heart," Le said.
"Carolina reapers in particular have been bred with heat in mind and are some of the hottest peppers in the world," he warned.
Fox News Digital also spoke with Ken Grey, an advanced practitioner (AP) and doctor of Oriental medicine (DOM).
Grey of Jupiter, Florida, follows Eastern medicine practices and believes that spicy food has a direct impact on the small intestine and heart.
"Foods that are naturally hot or spicy can help increase circulation and metabolism, thereby assisting with removing qi [energy] and blood flow blockages, improving heart health and digestion, while aiding in weight loss," Grey said.
"Some helpful foods in this category are chili peppers, cinnamon, nutmeg, cloves, cardamom, garlic and ginger."
Grey also advised home cooks to pay attention to the Scoville scale, which measures how hot peppers are.
Bell peppers typically clock 0 Scoville heat units (SHU) while jalapeños can be as high as 8000 SHUs, Grey said.
Grey did note that "balance is key."
"Hotter spices and peppers should be taken in moderation so as not to swing the pendulum too far in one direction."
"Hotter spices and peppers should be taken in moderation so as not to swing the pendulum too far in one direction," Grey said.
How do you know if you've eaten too much spice? Grey said if you overdo it, you may suffer from dry cough, heartburn and acid reflux, as well as stomach pain and cramping. Gastritis, diarrhea and headaches are also symptoms.
Modern studies aren't the only source of wisdom about the health benefits of spice, said Grey. He pointed to "thousands of years of culinary evolution."
"In Mexico and Guatemala, it is the magic of the chili pepper that unlocks iron found in their corn-rich diets," the expert said.
"Throughout Asia and many cultures, it is the chili peppers and spices that are used for [their] anti-microbial properties, which help to kill parasites."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Newsweek
22 minutes ago
- Newsweek
Curry Recall in 33 States as FDA Issues Risk Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A recall of curry sauces and pastes due to potential contamination with metal pieces has been issued the second-highest risk classification by the U.S. Food and Drug Administration (FDA). California-based company Jagpreet Enterprises LLC, trading as Sukhi's Gourmet Indian Foods, issued a voluntary recall for four products on July 23. The FDA later issued a Class II risk classification for the recall on August 11. Newsweek contacted the company for comment via email outside of normal office hours. Stock image. Jagpreet Enterprises LLC issued a voluntary recall for four products on July 23 due to potential metal contamination. Stock image. Jagpreet Enterprises LLC issued a voluntary recall for four products on July 23 due to potential metal contamination. Getty Images Why It Matters A Class II risk classification (one of three) refers to a situation in which the "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," according to the FDA. Foreign material in food products presents health risks, including choking, damage to teeth and digestive tract injury. Small pieces of metal could obstruct airways, especially in vulnerable populations like children and older adults. The recall involves a large quantity of ready-to-use curry pastes and sauces that were distributed 33 states, raising consumer safety and supply-chain concerns. What To Know The recall covers four separate products totaling 20,954 pounds, the FDA said. The products are: Sukhi's Classic Curry Paste - 5,030 pounds - UPC code: 7-67226-01001-4 - Lot numbers: 121371; 121728; 122844; 123312; 124047; 124085 - use-by dates: 06/11/26; 06/20/26; 09/17/26; 10/15/26; 11/30/26; 11/29/26 Sukhi's Tikka Masala Curry Paste - 9,930 pounds - UPC code: 7-67226-01005-2 - Lot numbers: 120995; 121085; 121452; 121531; 122378; 122586; 123970 - use-by dates: 04/18/26; 04/21/26; 06/17/26; 06/18/26; 08/26/26; 09/07/26; 11/16/26 Sukhi's Classic Curry Indian Curry Sauce - 1,125 pounds - UPC code: 7-67226-00165-4 - Lot numbers: 121203; 121418; 122714 - use-by dates: 04/17/26; 06/11/26; 09/03/26 Sukhi's Tikka Masala Indian Curry Sauce - 4,869 pounds - UPC code: 7-67226-00163-0 - Lot numbers: 120843; 121306; 121363; 121364; 121689; 121792; 121793; 122043; 122362; 122363; 122726; 123932; 124188; 124728 - use-by dates: 04/17/26; 06/09/26; 06/19/26; 06/28/26; 08/12/26; 09/13/26; 11/16/26; 12/25/26 The FDA listed the distribution pattern for all four products as spanning the following states: Arkansas, Arizona, California, Colorado, Florida, Georgia, Hawaii, Iowa, Idaho, Illinois, Indiana, Kansas, Louisiana, Massachusetts, Maryland, Michigan, Minnesota, Missouri, North Carolina, New Jersey, New Mexico, Nevada, New York, Ohio, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin. The FDA's update said that company had notified retailers about the recall by letter. What People Are Saying Dr. Mark Fischer, regional medical director at International SOS, told Newsweek previously: "It can be dangerous to consume metals or other foreign objects found in food... [They] can cause cuts or internal injury and may need to be removed via a surgical procedure. If you swallow any foreign objects, it's best to consult a healthcare professional." What Happens Next The recall is listed as ongoing, according to the FDA. Consumers who purchased the affected products should not consume them.
Yahoo
an hour ago
- Yahoo
Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton
New Episode Highlights the Painful, Often Misunderstood Reality of Living with Netherton Syndrome and the Urgent Need for Effective Treatments ASHBURN, Va., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ('Quoin' or the 'Company'), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of the fourth episode in its NETHERTON NOW video series. This installment features Mandy Aldwin-Easton, a Netherton Syndrome patient, and a widely recognized, passionate advocate for people living with rare diseases. Mandy serves as Medical and Communications Manager and Co-founder of the UK-based Ichthyosis Support Group and is President of the European Network for Ichthyosis. In the video, Mandy shares her personal journey living with Netherton Syndrome, from delayed diagnosis, severe, chronic pain, multiple hospitalizations to the profound long-term impact this disease has had on her life. 'One thing we don't talk about is how incredibly painful skin is when it doesn't work properly,' Mandy explains in the video. 'Imagine millions of paper cuts all over your body. It's just so highly unpredictable. The one thing anybody wants with a rare disease like Netherton Syndrome is hope—that better treatments are on the way.' Mandy's story underscores the severe physical and emotional toll of the disease. Despite having a highly supportive family and medical advocacy, she has experienced extreme flare-ups, prolonged hospitalizations, and a lack of targeted treatment options throughout her entire life. As an adult, she continues to navigate the complexities of a disease that many still fail to recognize as life-threatening. 'I couldn't go out because my skin was falling off me. It was so incredibly painful that it was just unbearable to walk,' she recalls. 'Even with hospital stays and treatments, no one really knew how to care for my skin.' 'Mandy has long been a pillar of the ichthyosis and Netherton Syndrome communities,' said Denise Carter, Co-Founder and Chief Operating Officer of Quoin Pharmaceuticals. 'Netherton Syndrome is not just a rare skin disease. It is a relentless and punishing condition marked by excruciating pain, debilitating flare-ups, recurrent infections, and emotional trauma. The toll on patients and their families is immense, not only physically and emotionally but also financially, requiring lifelong care, frequent hospitalizations, and ongoing interventions that place a heavy burden on families and healthcare systems. Beyond her personal resilience, Mandy's unwavering advocacy has made her a powerful voice for this underserved and often overlooked population. We are honored to feature her in our NETHERTON NOW series and remain steadfast in our mission to bring awareness and hope to those living with this devastating disease.' The release of this video comes as Quoin continues to advance its lead product candidate, QRX003, in multiple pivotal clinical trials for the treatment of Netherton Syndrome. Recently reported data from ongoing studies have shown highly encouraging improvements in key clinical outcomes. 'Mandy's story reflects the extraordinary strength and perseverance of patients who have endured a lifetime of suffering without access to an approved treatment,' said Dr. Michael Myers, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals. 'As we advance QRX003 through multiple late-stage pivotal trials, voices like Mandy's reinforce the urgency of our mission. Quoin is committed to delivering a meaningful treatment for the severely underserved Netherton Syndrome community and to driving forward research that addresses the significant unmet needs across a broader range of rare skin disorders.' The full video featuring Mandy Aldwin-Easton is available at: About QRX003QRX003 is a topical lotion formulated with a proprietary delivery technology that contains a broad-spectrum serine protease inhibitor, whose mechanism of action is intended to perform the function of a specific protein called LEKTI. The absence of LEKTI in Netherton patients leads to excessive skin shedding, resulting in a highly porous and compromised skin barrier. QRX003 is designed to promote a more normalized skin-shedding process and the formation of a stronger and more effective skin barrier. For more information about Quoin's current clinical trials, visit: About Quoin Pharmaceuticals Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, Scleroderma, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. For more information, visit or LinkedIn for updates. Cautionary Note Regarding Forward-Looking StatementsThe Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as 'expect,' 'intend,' 'hope,' 'plan,' 'potential,' 'anticipate,' 'look forward,' 'believe,' 'may,' and 'will,' among others. All statements that reflect the Company's expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: bringing awareness and hope to those living with Netherton Syndrome, continuing to advance QRX003 through multiple late-stage pivotal trials, delivering a meaningful treatment for the Netherton Syndrome community, driving forward research that addresses the significant unmet needs across a broader range of rare skin disorders and Quoin's products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, Scleroderma, , Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company's ability to deliver a safe and effective treatment for Netherton Syndrome; the Company's ability to pursue its regulatory strategy; the Company's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company's ability to complete clinical trials on time and achieve desired results and benefits as expected, the Company experiencing unanticipated or higher than expected clinical trial costs; and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. For further information, contact:Quoin Pharmaceuticals Myers, Ph.D., CEOmmyers@ Investor Contact:PCG AdvisoryJeff Ramsonjramson@ 863-6341
Yahoo
an hour ago
- Yahoo
Here's Why Halozyme Therapeutics (HALO) Traded Town in Q2
Meridian Funds, managed by ArrowMark Partners, released its 'Meridian Growth Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets made a significant rebound during the quarter, increasing 23% from intra-period lows to close at record highs. Against this backdrop, the fund returned 4.10% (net) compared to the Russell 2500 Growth Index's 11.31% return. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Meridian Growth Fund highlighted stocks such as Halozyme Therapeutics, Inc. (NASDAQ:HALO). Based in San Diego, California, Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company. The one-month return of Halozyme Therapeutics, Inc. (NASDAQ:HALO) was 11.11%, and its shares gained 12.32% of their value over the last 52 weeks. On August 11, 2025, Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock closed at $62.89 per share, with a market capitalization of $7.356 billion. Meridian Growth Fund stated the following regarding Halozyme Therapeutics, Inc. (NASDAQ:HALO) in its second quarter 2025 investor letter: "Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a leading drug delivery platform company built around its proprietary and commercially validated ENHANZE® technology. This innovative enzyme enables the subcutaneous delivery of biologics and fluids, transforming hours-long intravenous (IV) infusions into quick injections that can be delivered in just minutes. By doing so, ENHANZE can significantly reduce the treatment burden for patients and ease capacity constraints for healthcare providers. Shares of Halozyme declined during the period following news that the Centers for Medicare & Medicaid Services (CMS) may reconsider how it classifies reformulated drugs using ENHANZE. Under the proposed change, such formulations may no longer qualify as 'new drugs,' potentially subjecting them to Medicare price negotiations earlier than previously expected. While the proposal remains under review, we believe ENHANZE continues to offer meaningful advantages—including fewer injection-site reactions and substantial time and cost savings for clinics—making it an important innovation in drug delivery. We slightly reduced our position in the company during the quarter." An image of a research technician wearing lab coat with a syringe full of biopharmaceuticals. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 31 hedge fund portfolios held Halozyme Therapeutics, Inc. (NASDAQ:HALO) at the end of the first quarter, which was 25 in the previous quarter. In the second quarter of 2025, Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported revenue of $326 million, representing 41% year-over-year increase. While we acknowledge the potential of Halozyme Therapeutics, Inc. (NASDAQ:HALO) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Halozyme Therapeutics, Inc. (NASDAQ:HALO) and shared the list of most undervalued biotech stocks to buy. Halozyme Therapeutics, Inc. (NASDAQ:HALO) rose in the previous quarter due to strong earnings and its decision to focus on its core business. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data